Currently, higher levels of evidence are needed to characterize whether there are neuropsychiatric adverse effects associated with the use of levetiracetam in adults with epilepsy. For this reason, we will conduct a systematic review evaluating the occurrence of neuropsychiatric symptoms such as anxiety, depression, cognitive dysfunction, memory disorders, irritability, aggressiveness, impulsivity, behavioral disorders, suicidality, daytime sleepiness, and psychosis associated with levetiracetam use in adults with epilepsy without previously diagnosed psychiatric disorders. The search will be conducted in PubMed, Embase and Web of Science. Only clinical trials, observational studies, case reports and case series will be included. Quality assessment will be performed using the JBI critical appraisal tools.
levetiracetam, sintomas psiquiátricos, efectos adversos
|Short title||efectos adversos del levetiracetam|
|Effective start/end date||4/15/21 → 7/15/23|
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):
Main Funding Source
- Installed Capacity (Academic Unit)
- Bogotá D.C.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.